New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart ValvePRNewsWire • 03/31/25
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart RhythmsPRNewsWire • 03/27/25
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive IncomeThe Motley Fool • 03/26/25
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL SystemZacks Investment Research • 03/25/25
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 03/24/25
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery DiseasePRNewsWire • 03/24/25
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?Zacks Investment Research • 03/17/25
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money SeesSeeking Alpha • 03/17/25
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market ExpansionBusiness Wire • 03/04/25
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVADBusiness Wire • 03/04/25